Quintiles ranks #1 in contract research revenues based on 1996 earnings estimates, CEO says.
QUINTILES $517 MIL. REVENUES IN 1996 IS TOP IN CRO GROUP, Quintiles CEO Dennis Gillings maintained at Hambrecht & Quist's health care conference Jan. 7 in San Francisco. The total sales figure takes into account revenues generated from subsidiaries acquired during the year, including the Innovex peri-launch marketing organization, the medical device consultants BRI and the health policy firm Lewin. Corning's CRO spin-off, Covance, ranks second by 1996 revenue estimates, at about $490 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth